Signalling pathways involved in clinical responses to chemotherapy

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Chemotherapy and radiotherapy induce complex cellular signaling, activating both apoptosis (cell death) and survival pathways.
• Tumor-specific genetic alterations can modify these pathways, leading to inter-patient variability in treatment response.
• Key survival pathways include ERK, AKT, and nuclear factor-kappaB, while JNK/p38 MAP-kinases are involved in cell death.

Purpose of the Study:

• To explore the balance between cell death and survival pathways in determining chemotherapy efficacy.
• To investigate strategies for modulating survival pathways to enhance chemotherapy effectiveness.
• To highlight the potential impact of novel molecules and technologies on patient survival.

Main Methods:

• Analysis of signaling pathways (ERK, AKT, NF-kappaB, JNK/p38 MAP-kinases) activated by chemotherapy and radiotherapy.
• Examination of genetic alterations influencing these pathways in various tumors.
• Review of current and emerging strategies for modulating cancer cell survival.

Main Results:

• Chemotherapy efficacy is determined by the dynamic balance between induced cell death and survival signaling.
• Individual tumor characteristics and genetic profiles influence the specific pathways activated.
• Conventional chemotherapy strategies have shown limited success in overcoming survival mechanisms.

Conclusions:

• Modulating cancer cell survival pathways is crucial for increasing chemotherapy efficacy.
• New therapeutic molecules targeting survival pathways and advanced tumor analysis technologies hold promise for improving patient survival.
• Personalized treatment approaches based on individual tumor biology are essential for optimizing cancer therapy.